EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

Is this the Best Time to Add Illumina (ILMN)? — Oct 16th, 2024

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund’s Investor Class fund ARTMX returned 2.35%, Advisor Class fund APDMX posted a return...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers — Oct 9th, 2024

Designed to make next-generation sequencing accessible to more labs With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader ...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

Here's Why Illumina (ILMN) is a Strong Momentum Stock — Oct 8th, 2024

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks...

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening — Oct 10th, 2024

Exact Sciences EXAS recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening. This approval solidifies the company's leadership in the non-invas...

OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies — Oct 11th, 2024

OPKO Health, Inc.’s OPK company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Depar...

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold? — Oct 18th, 2024

Shares of Illumina ILMN have been showcasing impressive market performance, reaching a new 52-week-high of $151.04 during Tuesday’s trading session. The stock finished at $143.52 yesterday, just 5.2% short of its peak. The surge comes soon after the company's announcement on Oct. 9 of ...